Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?

Pomerantz LLP filed a class action lawsuit against Insulet Corporation (NASDAQ: PODD) and certain officers, alleging securities violations. The suit covers investors who acquired Insulet securities between February 21, 2025, and May 26, 2026. The complaint claims Insulet made false statements about its manufacturing controls and product safety. Insulet's stock price fell 6.88% and 5.07% following two voluntary medical device corrections in March and May 2026, respectively.

Bernstein Liebhard LLP said a shareholder filed a securities class action against Insulet Corp. (NASDAQ: PODD) for investors who bought shares between Feb. 21, 2025 and May 26, 2026. The suit alleges materially false or misleading statements and omissions about operations, growth prospects, and financial stability, leading to inflated prices and losses. Lead plaintiff papers due Aug. 31, 2026.

Insulet (PODD) reported Q2 2026 revenue of $801.7M, up 22.7% constant currency and above guidance. Adjusted EPS was $1.66, up 41.5%. U.S. Omnipod revenue was $544.1M, and international was $251.8M. Management revised U.S. full-year Omnipod growth to 17% to 19% and raised international to 30% to 32%, citing weaker type 2 retention.

Insulet reported Q2 2026 results and said U.S. revenue guidance for 2026 was lowered to 20% to 22% growth due to lower-than-expected type 2 retention and utilization, especially in the first 90 days. The company is shifting sales incentives to prioritize retention, investing in Omnipod Discover, expanding customer care, and expects 2026 free cash flow to decline modestly.

Insulet (NASDAQ:PODD) said execution issues hurt its U.S. Type 2 outlook and outlined steps to improve onboarding, customer support, retention-focused sales incentives, and use of Omnipod Discover. It raised 2026 guidance to 20% to 22% constant-currency total revenue growth and 21% to 23% Omnipod growth, with Q3 growth forecasts. Cash was $535M.

Insulet (NASDAQ:PODD) reported Q2 revenue of $801.7 million, up 23.5%, above guidance. Omnipod revenue rose 24.6%, with U.S. up 20.1% and international up 35.5%. It lowered full-year U.S. Omnipod growth to 17% to 19% from 20% to 22%, and total revenue to 20% to 22%. Adjusted EPS rose 41.5% to $1.66.